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Abstract
Background: In coronary artery bypass grafting surgery, arterial conduits are preferred because of more favourable
long-term patency and outcome. Anyway the greater saphenous vein continues to be the most commonly used
bypass conduit. Minimally invasive endoscopic saphenous vein harvesting is increasingly being investigated in order
to reduce the morbidity associated with conventional open vein harvesting, includes postoperative leg wound
complications, pain and patient satisfaction. However, to date the short and the long-term benefits of the
endoscopic technique remain controversial. This study provides an interesting opportunity to address this gap in
the literature.
Methods/Design: Endoscopic Saphenous harvesting with an Open CO2 System trial includes two parallel vein
harvesting arms in coronary artery bypass grafting surgery. It is an interventional, single centre, prospective,
randomized, safety/efficacy, cost/effectiveness study, in adult patients with elective planned and first isolated
coronary artery disease. A simple size of 100 patients for each arm will be required to achieve 80% statistical
power, with a significant level of 0.05, for detecting most of the formulated hypotheses. A six-weeks leg wound
complications rate was assumed to be 20% in the conventional arm and less of 4% in the endoscopic arm.
Previously quoted studies suggest a first-year vein-graft failure rate of about 20% with an annual occlusion rate of
1% to 2% in the first six years, with practically no difference between the endoscopic and conventional
approaches. Similarly, the results on event-free survival rates for the two arms have barely a 2-3% gap. Assuming a
10% drop-out rate and a 5% cross-over rate, the goal is to enrol 230 patients from a single Italian cardiac surgery
centre.
Discussion: The goal of this prospective randomized trial is to compare and to test improvement in wound
healing, quality of life, safety/efficacy, cost-effectiveness, short and long-term outcomes and vein-graft patency after
endoscopic open CO2 harvesting system versus conventional vein harvesting.
The expected results are of high clinical relevance and will show the safety/efficacy or non-inferiority of one
treatment approach in terms of vein harvesting for coronary artery bypass grafting surgery.
Trial registration: www.clinicalTrials.gov NCT01121341.
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Since the introduction of saphenous vein grafting by
René Favaloro in the 1968, coronary artery bypass graft-
ing (CABG) surgery has become one of the most com-
mon surgical procedures performed [1]. Although
approximately 15% to 20% of vein grafts occlude in the
first year with an annual occlusion rate of 1% to 2% in
the first six years and 4% to 5% from 6 to 10 years, the
greater saphenous vein continues to be the most com-
monly used bypass conduit [2].
Minimally invasive endoscopic saphenous vein har-
vesting was introduced by Lumsden in 1995 [3,4]. Ever
since it has been increasingly investigated in order to
reduce the morbidity associated with conventional open
vein harvesting, which requires long incisions, and thus
postoperative leg wound complications, pain and patient
dissatisfaction [5-7].
Data from the Society of Thoracic Surgery National
Database (accessed at http://www.sts.org) show that in
2008 endoscopic harvesting was used in approximately
70% of CABG surgeries performed in USA, while in
Europe its use is for various reasons still limited.
In 2005, the International Society for Minimally Inva-
sive Cardiothoracic Surgery published a consensus state-
ment on the use of endoscopic vein harvesting (EVH)
versus open vein harvesting (CVH) in CABG aimed to
determine which resulted in better clinical and resource
outcomes [8]. The members of the consensus committee
concluded that EVH was recommended to reduce leg
wound related complications, decrease postoperative
pain, accelerate postoperative mobility, improve patient
satisfaction, reduce length of stay in the hospital, and use
of outpatient wound-management resources; as to the
quality of the conduit harvested, major adverse cardiac
events (MACE) and angiographic patency at 6 months,
EVH and CVH techniques were judged to fare equally.
As now, the evidence for short-term patient benefits
in reducing infections and operative complications while
improving patient mobility and satisfaction is sufficiently
replete, including the conclusion that wound complica-
tion management following EVH requires significantly
less resource utilization than for CVH and thus increase
its cost-effectiveness [9].
The mid- and long-term outcome are instead still
controversial issues. This may be partly due to the fact
that the event-free survival rate over periods from 2 to 5
years is commonly taken as a surrogate marker for graft
failure, since postoperative angiographic studies, the
gold standard to evaluate thel o n g - t e r mi n f l u e n c eo f
vein harvest technique on graft patency, are not widely
used owing to their low practicality and high costs.
A recent pooled meta-analysis of all observational and
randomized trials of short- to midterm follow-ups
shows no differences in survival [10]. Allen et al. [11]
quote as outcome of their 112 prospectively randomized
patients a freedom from MACE at five years of 75% for
EVH vs. 74% for CVH, which leads them to conclude
that the use of endoscopic versus traditionally harvested
saphenous vein does not influence event-free survival. A
different opinion is instead voiced by Lopes et al. [12]
who carry out a single retrospective post hoc analysis of
the PREVENT IV trial, and, based on the event-free sur-
vival rates at three years of 80% for EVH vs. 83% for
CVH, conclude that EVH may have a negative impact
on graft patency. Actually, the relatively small gap
between the event-free survival rates for the two
approaches (1-3%) would require enormously large sam-
ple sizes to be established with a statistical power of at
least 80%.
The comparison and discussion of EVH vs. CVH
results often neglects to consider the impact of the use
of endoscopic devices for vein harvesting which differ
both for dissection technique and usage of CO2. Cheng
et al. [13] underline that the Lopes’ conclusions on the
PREVENT IV trial may have been influenced by the fact
that large part of the analysed EVH cases were per-
formed with a closed CO2 system device (GUIDANT)
which has a documented tendency to form clots within
the vein, if heparin is not given before dissection (as it
was actually the case at the times of that trial). They
add other indications of device-related different out-
comes: a long-term randomised controlled trial (RCT)
carried out with a Ethicon (now Sorin) device showed in
a 5-year follow-up no difference in MACE, while two
others RCTs and a subset data of the PAS-Port proximal
anastomosis system trial using Guidant (now Maquet)
showed non-significant trends in worse vein-graft
patency following EVH.
The device used and all the related technicalities with
the ongoing improvements over the years may well be
the divide among different evaluations. As a conse-
quence, great care must be used when comparing results
from trials carried out several years apart from each
other.
These considerations formed the rationale for our
Endoscopic Saphenous harvesting with an Open CO2
System (ESOS) Trial, whose protocol is herein
illustrated.
Methods/Design
The study site for this trial is the Department of Thor-
acic Surgery, Division of Cardiac Surgery of San Gio-
vanni Battista Hospital-University of Turin, Italy. This
center has a long-term well-established familiarity with
minimally invasive techniques; from here stems the
decision to extend to CABG the practice to endoscopic
saphenous vein harvesting, in order to improve clinical
outcomes and provide major benefits to patients.
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chosen, in the first half of 2010, prior to trial patient
recruitment, there has been a 6-months break-in period
dedicated to satisfactorily complete all aspects of the
learning curve. 20 patients scheduled to have coronary
artery bypass grafting judged amenable to the endo-
scopic approach were enrolled. This number is consis-
tent with what reported by authors who went through
the same learning curve process [14-16].
All results obtained in this period concur to state that
the mastery of the vein harvesting technique has been
successfully achieved [17,18]. The total procedure time
and the number of incisions have decreased, while the
vein harvest rate, or length-time index has consistently
increased to reach the value of 1 cm/min suggested by
Crouch et al. [19] as optimal for this method (95% CI:
0.89-1.04). Other important results have been low inci-
dence of wound-related morbidities, absence of infec-
tion, no need for hospital re-entry or ambulatory
medications after discharge, general satisfaction
expressed by all patients for the prompt wound healing,
the good mobility, the absence of pain and the presence
of a very small scar, due to become soon scarcely
discernible.
In order to ensure that during the trial all vein har-
vesting procedures with all their technicalities will be
carried through uniformly, and thus avoid a further stra-
tification, the vein harvesting is planned to be performed
by a single surgeon (A.C.). Should other surgeons be
enrolled, a careful evaluation of homogeneity of results
from the different operators will be mandatory.
Ethics and Trials Registration
The study is funded by a 2010 grant from the Azienda
Ospedaliera-Universitaria San Giovanni Battista of
Turin. The trial has been approved by the local Ethic
Committee and registered at the United States National
Institutes of Health Clinical Trials Registry (Clinical-
Trials.gov ID NCT01121341), available online at http://
www.clinicaltrials.gov.
Primary end points
We have two primary end points (see Appendix 1) with
different deadlines:
￿ a short-term one (6 weeks after CABG surgery),
regarding freedom from wound complications,
defined as cellulitis, edema, ecchymosis, hematoma,
cellulites, drainage, necrosis, dehiscence, debride-
ment; leg wound infection according to ASEPSIS
score;
￿ a long-term one (2 years after CABG surgery),
regarding freedom from MACE, i.e. death, myocar-
dial infarction, recurrent angina or congestive heart
failure due to vein graft failure with assessment of
vein-graft patency.
Secondary end points
The secondary end points (see Table 1) include for both
arms:
￿ identification of predictors for a possible develop-
ment of a harvest-site complication: preoperative
demographics such as sex, obesity, diabetes, periph-
eral vascular disease and operative demographics
such as EVH vs. CVH approach, number of bypass
grafts, time on bypass, harvest site (below or above
the knee), characteristics of the bandage will be con-
sidered and analyzed;
￿ evaluation of differences between EVH and CVH
in operative time, mobility time, number of medica-
tions, hospital length of stay, readmission for leg
wound complications or need for outpatient wound
management resources and generally in all resources
that need to be allocated;
￿ Evaluation of differences between EVH and CVH
in the quality of the harvested venous conduits;
￿ Comparison of health-related quality of life
(EUROQol-5D) and leg pain score and identification
of factors, in addition to treatment allocation, that
are associated with variations in quality of life
outcomes.
￿ correlation of the long-term outcome with the vein
histological scores determined at harvest time.
For the EVH arm only:
￿ effect of the harvest site, whether below or above
the knee;
￿ effect of the vein preparation solution;
￿ effect of an uncontrolled distension pressure or no
touch technique on vein patency and long-term
outcomes;
￿ assessment of systemic carbon dioxide absorption.
ESOS is meant to be an interventional, single cen-
tre, prospective randomized study with an all-
comers design. Each cohort will initially be formed
by 115 patients. This number has been selected to
balance statistical requirements and resource
limitations.
In the course of the trial all consecutive adult patients
(18 years and older) with elective planned and first iso-
lated coronary artery disease (CAD) amenable to coron-
ary artery bypass grafting surgery will be screened to
establish their eligibility to both EVH and CVH on the
basis of the guidelines reported in Table 1.
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who are expected to have a better outcome with one of
the two, will not be included in the trial; neither will be
the patients who refuse to be randomized because of their
personal preference for one approach over the other.
Patients deemed amenable for both harvesting modal-
ities, after having signed the informed consent, will be
assigned by means of a standard web-based computer
generated randomization scheme to one of the two
cohorts, either EVH or CVH, and after allocation they
will be included in the intention to treat analysis. An
independent clinical research assistant will be responsi-
ble for randomization and treatment assignment.
The post surgery follow-up will consist of clinic visits
on the sixth week after CABG surgery and at occurrence
of any adverse event. Each information leading to in-
patient or out-patient treatment regarding major adverse
cardiac events, vein-graft failure or occlusion or other
morbidity, will be collected. The number of visits
required to clear up each wound complication will be
used as a surrogate to determine outpatient resource
utilization for wound management.
Follow-up angiograms will be performed at 18 months
to explore directly vein graft longevity. This will allow
not to rely totally on the indirect, and sometimes
deceiving, information supplied by the event-free survi-
val rates.
Follow-up will stretch over a minimum of 24 months.
A tt h ee n do ft h i sp e r i o dt h e r ew i l lb ea na s s e s s m e n to f
the state of the art based on the results obtained with the
two different approaches, whose rationale will lead to the
decision to either conclude or continue the follow-up.
Trial Population, and Statistical Analysis
To assess accurately the trial, the study investigators
have followed the CONSORT 2010 checklist with meth-
odological rigour [20].
Study recruitment has initiated in August 2010. Figure
1 illustrates the planned study flowchart, and Table 1
reports its details.
All data relative to enrolled patients will be entered in
a database containing preoperative demographics and
risk factors (age, sex, BMI, morbidities, coronary artery
lesions severity by SYNTAX score and surgical risk pro-
file by EUROscore, etc), intra-operative variables (site of
harvesting, number of incisions, lengths, times, etc), vein
specific variables, pre- and post- harvesting respiratory
and hemodynamic parameters, histological status of the
harvested vein, as examined and graded by a pathologist.
Wound healing and variables in the ASEPSIS score and
other wound-related morbidities, wound complications,
outcome and correlated events of the follow-up are to
be evaluated by an independent clinical committee every
6 weeks in the first year, and then at 18 and 24 months.
The total number of data characterizing each patient
will be approximately 180, a complete scenario of his
risk factors, surgical and post surgery history, short-,
mid- and long-term outcome. The two cohorts will
hence be described by two 115 × 180 arrays, with the
intention to bring to light differences and similarities in
behaviors and trends by means of a thorough statistical
analysis.
T h ec o n t i n u o u sd a t aw i l lb er e p o r t e da sa v e r a g e±
standard deviation and will be analyzed by standard
ANOVA tests. Discrete or dichotomous values will be
reported as percentages, risk ratios (and their 95% confi-
dence intervals), and will be stratified in mxn contin-
gency tables, analyzed for significant differences by chi-
square tests (with Yates’correction in the case of 2 × 2
tables) and Fisher or mid-P tests.
The freedom from late wound complications and in
general all event-free survival rates will be obtained
according to the Kaplan-Meyer method, with the statisti-
cal differences among them estimated by the Mantel-Cox
Table 1 Study design
Inclusion Criteria: Exclusion Criteria:
Elective planned CABG surgery Emergency revascularization: patients with hemodynamic instability or requiring inotropic
or intra-aortic balloon support
First isolated CABG surgery Previous cardiac surgery
Adult patients (18 years and older) and competent to
give informed consent
Planned concomitant valve surgery
Bad varicous veins
Previous safenectomy
History of deep vein thrombosis
History of suffered trauma on the lower extremity
Preoperative legs immobilization
Previous leg wound complications
Coexisting illness with life expectancy < five years
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determined at a p value (probability of null hypothesis:
the observed differences are imputable to chance) ≤ 0.05,
corresponding to the false positive probability (a or type
I error). In case of a p value > 0.05, the next step will be
the estimate of the test power II a n dt h er e l a t e df a l s e
negative probability (b or type II error = 1- II).
A few considerations on the selected sample size are
opportune. Assuming the values conventionally accepted
for the drop-out and cross-over rates of ≤ 10% and ≤
5% of the patients, follow-up will see two cohorts of
approximately 100 patients for each. This means that
data computed as percentage within each cohort should
be correctly reported with an uncertainty of ± 5%.
It is well known that the power of the statistical test
used to carry out comparisons between two sets of data
depends both on the sample sizes and the entity of the
difference between data observed in the two groups. A
tiny difference has difficulty to be evidenced as statistical
significant even with a very large sample size, while a
substantial difference can be easily assessed as signifi-
cant even with a small sample size.
In a trial in which the analysis wants to take into
account several outcomes, the presence of a wide range
of observable differences makes very difficult a “valid-for-
all” estimate of the sample size necessary to achieve the
desired test power (usually 80%) or inversely on the test
power predicted on the base of the actual sample size.
In our trial, as far as the short-term outcome is con-
cerned, previous studies [8,9] suggest a six-week leg
wound complication rate of about 20% in the CVH arm
and less than 4% in the EVH arm. With this risk/preva-
l e n c ed i f f e r e n c eo f1 6 % ,a n dt h ep r e d i c t e ds a m p l es i z e
of 100, the power based on normal approximation is
about 94% (91% if we apply the continuity correction),
and thus very good: a power of about 80% would be
reached already with a sample size around 80.
The situation changes dramatically when we consider
the mid- and long term outcomes. Previously quoted
studies [2] suggest a first-year vein-graft failure rate of
about 20% with an annual occlusion rate of 1% to 2% in
the first six years, with practically no difference between
the EVH and CVH approaches. On the basis of previous
comparative trials of EVH versus OVH, none of the
clinically relevant cardiovascular outcomes differed sig-
nificantly for EVH compared with OVH (Allen et al.
[11] reported survival free of MACE at up to 5 years as
75% vs. 74%, p = 0.85). A 2-3% of non-inferiority margin
is therefore planned in this protocol study. The 80% test
power goal, with such small risk prevalence difference
requires sample sizes of at lest 3000 for each cohort,
values well beyond any practical implementation in a
single medical centre, at least in a lifetime.
On the basis of these considerations, the initial
recruitment number of 115 patients per cohort, with
end-point number of about 100 patients, sustainable
from the point of view of human and financial
resources, looks fully acceptable.
Procedural techniques
The leg wound protocol established for the trial calls for
all patients, irrespective of the cohort to which they
have been allocated, to receive 1 g cefazolin and 1 g
vancomycin hydrochloride (Vancocin) preoperatively.
They will also receive a povidoneiodine (Betadine) scrub
and preparatory solutions before skin incision.
Antibiotic therapy will be continued for an additional
48 hours post-operatively. All wounds will be closed at
the time of heparin reversal and the administration of
protamine.
Figure 1 Flowchart of the study design. This figure illustrates the
study design.
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Conventional vein harvesting will be performed through
longitudinal incisions over the course of the saphenous
vein (SV), starting at the medial malleolus. The length
of the incision will depend on the amount of vein
required (at least a minimum of 18-20 cm per each vein
segment). The incisions will be closed in layers, with
absorbable subcutaneous and subcuticular sutures. Elas-
tic bandage wrapping or support stockings will be used
in all patients, until up to at least 72 hours after
harvesting.
Endoscopic vein harvesting
A 2,5 cm longitudinal incision will be made in the thigh
above the knee (two finger-breadths posterior to the
medial edge of the tibia). After initial identification of
the saphenous vein, a plane of dissection along the ante-
rior surface of the vein will be performed using as endo-
scopic dissector the Sorin ClearGlide, an open CO2
EVH system. This device is not dependent on gas insuf-
flation to maintain tissue separation and/or the tunnel.
The insufflator of the endoscopic-tower is capable to
regulate the gas flow and maintain a zero gradient pres-
sure in the cavity. A low flow of CO2 is required (4 l/
min) to flush the working channel and optimize the
vein exposure.
Vein harvesting will be initially directed proximally
until 2 cm below and lateral to the pubic tubercle,
where the SV enters the cribriform fascia (fascia lata)t o
join the femoral vein. Then, depending on the amount
of vein required, distal (below the knee) harvesting may
be extended until the medial malleolus. Branches will be
divided using an electrothermal bipolar tissue-sealing
cautery (Ligasure™ 5 mm Laparoscopic Instrument Val-
leylab). SV will be divided distally to initial incision
using endoclips (Endosurgery) and endoforceps (Sor-
inGroup), and a small stab incision will be made to pull
the vein.
The incision will be closed with absorbable subcuta-
neous and subcuticular sutures, starting after reversal of
the heparin infusion. Elastic bandage wrapping or sup-
port stockings will be used in all patients, up to at least
72 hours after harvesting.
After harvesting, the vein will be cannulated and pre-
pared with papaverine and heparinised blood, and
branches will be ligated using titanium clips or/and 3-0
silk ties.
Histology
A first check on the validity of the endoscopic device
(given for granted the surgeon’s ability) may be furn-
ished by the histological evaluation of specimens col-
lected during the harvest, with the assessment of the
level of disruption in the various layers of the venous
wall. Absence, or minimal presence of disruption should
constitute a good start for a satisfactory vein outcome.
The uniformity, continuity, and integrity of vein struc-
tures will be assessed by histological studies conducted
in a blind fashion by two of the authors (L.M. and S.A.),
who will evaluate the vein histological structures accord-
ing to the so-called “Griffith score” [21] which estimates
the percent disruption of each histological structure (see
Table 2).
At this purpose it is important to point out that the
results obtained on the specimens collected during the
learning curve are very encouraging: the average overall
score is 0.3 ± 0.6 over a total of 4.0, with a flat “zero”
(intact structure) for the medial connective tissues, med-
ial smooth muscles and adventitial connective tissues.
Another open issue is whether the vein preparation
procedure might influence SV histology. As now, there
is no standard vein-preparation solution used in clinical
practice [22,23]. The authors will investigate whether
the preparation solution and a controlled distension
pressure or no touch technique might prevent histologi-
cal disruption and influence vein patency and long-term
outcomes. (Appendix 1)
Discussion
Nowadays, a research to evidence benefits, harms and
resource implications of EVH vs. OVH must not only
meet the requirements of being prospective, randomized
and including a great number of baseline, inter-opera-
tive, post-operative and follow-up co-founding variables,
but needs also to exploit the latest improvements in the
available technologies of vein harvesting.
T h eE n d o s c o p i cS a p h e n o u sharvesting with an Open
CO2 System (ESOS) Trial, was configured after these
guidelines.
Its primary goal is to compare and to quantify
improvements in short and mid-term outcomes after
endoscopic open CO2 harvesting (EVH) versus conven-
tional open vein harvesting (CVH): safety/efficacy, leg
wound infections and morbidity, patient satisfaction,
short and long-term outcome, with histological and
angiographic studies will be matter of thorough
investigation.
The results on wound healing, mobility, patient satis-
faction, health-related quality of life, safety/efficacy,
cost-effectiveness are expected to be available shortly
after the beginning of the trial. The mid-term outcomes
and vein-graft patency will be estimated at the end of
the 2-year follow-up, when a possible extension of the
period of observation will also be considered.
A secondary goal of ESOS is to provide guidance to
physicians on optimal CABG strategies for patients with
different risk levels. A more widely spread and accurate
knowledge on this issue may also help patients in their
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have to take fundamental decisions for their health.
When compared to CVH procedure, EVH is expected
to confer a 16% reduction in leg wound infections. If
the use of new improved instrumentation will also
improve the long-term event-free survival rate, as we
hope, endoscopic saphenous vein harvesting should then
be definitely recommended to patients with CAD, also
for the high level of satisfaction usually reported by
patients undergoing this minimally invasive procedure.
This study, besides providing new information aimed
to improve the quality of care for CAD patients, will
also assess the cost/effectiveness of this approach as far
as in-patient and out-patient care is concerned.
Trial status
Currently including patients
List of abbreviations used
ESOS: Endoscopic saphenous harvesting with an open CO2 system; CABG:
Coronary artery bypass grafting; CAD: Coronary artery disease; PCI:
Percutaneous coronary intervention; EVH: Endoscopic vein with open CO2
harvesting; CVH: Conventional vein harvesting; SV: Saphenous vein; MACE:
Major adverse cardiovascular events: death; myocardial infarction;
revascularization (PCI or CABG) for ischemia or angina recurrence; GF: vein-
graft failure at least 75% of stenosis at angiographic study; GO: vein-graft
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